Generation of BR-EBVSTs from patient PBMCs. T2- and BR-EBVSTs were generated from the cryopreserved PBMCs of patients with EBV⁺ lymphoma who had received T2-EBVSTs infusions in our clinical trial (#NCT01555892), and were characterized for their proliferation, and antigen-specific function. (A) Fold expansion of W- and RAD-EBVSTs from day 0 to 16. Statistical comparisons were determined using paired 2-tailed Student t test. P < .05, (P = .12 [ns, nonsignificant], ∗P = .033, ∗∗P = .002, and ∗∗∗P < .001. Data shown are plotted as mean ± SEM. (B) Frequency of IFN-γ SFCs per 10⁵ in response to T2- and BR-pepmix stimulation on day 16 as measured in ELISpot assays. (C) Killing of EBV pepmix–pulsed (straight lines) or –nonpulsed (dotted line) autologous aATCs by BR-EBVSTs from 4 patients in a 4-hour ⁵¹Cr chromium-release assay. Each patient BR-EBVST is represented by a colored line.